- Home
- TRIP vs MNKD Comparison
TRIP vs MNKD Comparison
Compare TRIP & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | MNKD |
|---|---|---|
| Founded | 2000 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2011 | 2004 |
Fundamental Metrics
Financial Performance| Metric | TRIP | MNKD |
|---|---|---|
| Price | $13.22 | $5.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $15.98 | $10.08 |
| AVG Volume (30 Days) | 2.4M | ★ 3.7M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.53 | 23.47 |
| EPS | ★ 0.59 | 0.10 |
| Revenue | ★ $1,891,000,000.00 | $313,787,000.00 |
| Revenue This Year | $5.18 | $21.40 |
| Revenue Next Year | $4.97 | $25.03 |
| P/E Ratio | ★ $22.59 | $55.78 |
| Revenue Growth | 4.25 | ★ 17.43 |
| 52 Week Low | $10.43 | $3.38 |
| 52 Week High | $20.16 | $6.51 |
Technical Indicators
Market Signals| Indicator | TRIP | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 46.52 |
| Support Level | $12.98 | $5.03 |
| Resistance Level | $14.05 | $6.05 |
| Average True Range (ATR) | 0.54 | 0.29 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 10.44 | 35.04 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2024, and TheFork, its dining brand, represented 10% of sales (about 8% of revenue were intersegment, which are eliminated from consolidated revenue).
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.